VS Pharma SRL
4.1 FTEThe score of VS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +63 % Total assets +27 % Headcount (avg FTE) +17 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
VS Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 107,287 € | ||||
| Equity | 720,364 € | ||||
| Cash | 109,585 € | ||||
| EBITDA | 253,429 € | ||||
| Total assets | €1.20m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 28 Aug 2024
- Year ended 31 Dec 2022filed on 29 Sep 2023
- Year ended 31 Dec 2021filed on 23 Aug 2022
VS Pharma's financial analysis
- Solvency60.1%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of VS Pharma
VS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0827.022.196
- VAT number
- BE0827022196
- Peppol
- Registered · 0208:0827022196 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Jun 2010
- Registered office
- 4052 Chaudfontaine
- Size
- Micro · 4.1 FTE
- Latest accounts
- 2025 · filed on 26 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
VS Pharma (SRL) has been based in Chaudfontaine since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 107,287 € and equity of 720,364 €; its revenue is not published. With 4.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 60.1%, above the median of its sector (41.5%).
Companies similar to VS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Marc Thoné Retail sale of pharmaceutical products Antwerp · balance sheet 93,815 €
- Millenium Pharma Retail sale of pharmaceutical products Ganshoren · balance sheet €1.15m
- Apotheek I. DE Bauw Retail sale of pharmaceutical products Putte · balance sheet €1.14m
- Pharmacie C. Bernard Retail sale of pharmaceutical products Seraing · balance sheet €1.28m
- America Nieuwerkerken Retail sale of pharmaceutical products Nieuwerkerken (Limb.) · balance sheet €1.44m
- LES Pharmacies Lambrechts Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet 896,725 €
- Apo-M Retail sale of pharmaceutical products Kortenberg · balance sheet 852,674 €
- Ralinvest Retail sale of pharmaceutical products Ghent · balance sheet €1.22m
Frequently asked questions about VS Pharma
What is the revenue of VS Pharma?
VS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of VS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0827022196 for VS Pharma, if the company is VAT-registered. Its company number (CBE) is 0827.022.196.
Where is the registered office of VS Pharma?
According to the CBE register, the registered office of VS Pharma is in 4052 Chaudfontaine.
What is the equity of VS Pharma?
At the close of the 2025 financial year, the equity of VS Pharma amounts to 720,364 €, a solvency of 60.1% of total assets.
How many people work at VS Pharma?
4.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages VS Pharma?
The register lists 2 active mandates at VS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of VS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →